Quantitative analysis of human heart valves: Does anorexigen exposure produce a distinctive morphological lesion?

Cardiovascular Pathology

Volumn 11, Issue 5, 2002, Pages 251-262

  McDonald, Paul C ^a,b   Wilson, Janet E ^a,b   Gao, Min ^b   McNeill, Shannon ^a,b   Spinelli, John J ^b   Williams, O Dale ^c   Harji, Salima ^a,b   Kenyon, Jennifer ^a,b   McManus, Bruce M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c University of Alabama at Birmingham   (United States)

Author keywords

Anorexigen exposure; Carcinoid valve disease; Fenfluramine; Floppy valve disease; Heart valve; Phentermine; Quantitative image analysis; Rheumatic valve disease

Indexed keywords

ANOREXIGENIC AGENT; GLYCOSAMINOGLYCAN;

ARTICLE; BLOOD VESSEL; CARCINOID SYNDROME; CLINICAL FEATURE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG EXPOSURE; FEMALE; GEOMETRY; HEART VALVE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHEUMATIC HEART DISEASE; THICKNESS; VALVULAR HEART DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APPETITE DEPRESSANTS; CARCINOID HEART DISEASE; DISCRIMINANT ANALYSIS; FEMALE; FENFLURAMINE; GLYCOSAMINOGLYCANS; HEART VALVE DISEASES; HEART VALVES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MITRAL VALVE PROLAPSE; PHENTERMINE; RHEUMATIC HEART DISEASE;

EID: 0036754973     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(02)00110-2     Document Type: Article

References (43)

1. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
2. Khan M.A., Herzog C.A., St. Peter J.V., Hartley G.G., Madlon-Kay R., Dick C.D., Asinger R.W., Vessey J.T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 339:1998;719-724.
3. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med. 339:1998;725-732.
4. Burger A.J., Sherman H.B., Charlamb M.J., Kim J., Asinas L.A., Flickner S.R., Blackburn G.L. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol. 34:1999;1153-1158.
5. Kancherla M.K., Salti H.I., Mulderink T.A., Parker M., Bonow R.O., Mehlman D.J. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol. 84:1999;1335-1338.
6. Lepor N.E., Gross S.B., Daley W.L., Samuels B.A., Rizzo M.J., Luko S.P., Hickey A., Buchbinder N.A., Naqvi T.Z. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol. 86:2000;107-110.
7. Teramae C.Y., Connolly H.M., Grogan M., Miller F.A. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc. 75:2000;456-461.
8. Fisher J.E., Orlandi Q., Ruden R., Price D., Istfan N., Joziatis B.T. Valvular regurgitation in subjects receiving anti-obesity agents: a consecutive series with follow-up. J Am Soc Echocardiogr. 12:1999;370.
9. Kimmel S.E., Keane M.G., Crary J.L., Jones J., Kinman J.L., Beare J., Sammel M., Sutton M.S., Strom B.L. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol. 84:1999;304-308.
10. Gardin J.M., Schumacher D., Constantine G., Davis K.D., Leung C., Reid C.L. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. J Am Med Assoc. 283:2000;1703-1709.
11. Wee C.C., Phillips R.S., Aurigemma G., Erban S., Kriegel G., Riley M., Douglas P.S. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med. 129:1998;903-905.
12. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
13. Eichelberger J.P., Pearson T.A., Gajary E. Fifteen year outcome data on patients treated with fenfluramine-phenermine combination. J Am Soc Echocardiogr. 12:1999;355.
14. Mast S., Jollis J., Ryan T., Landolfo C., Crary J. The natural histology of fenfluramine-associated valvulopathy assessed by echocardiography. J Am Coll Cardiol. 35:2000;523A.
15. Cannistra L.B., Cannistra A.J. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment. NeuroReport. 9:1998;2989-2993.
16. Hensrud D.D., Connolly H.M., Grogan M., Miller F.A., Bailey K.R., Jensen M.D. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc. 74:1999;1191-1197.
17. Mancini M.C., Leite C.C., Grinberg M., Halpern A. Regression of heart-valve abnormalities after discontinuation of dexfenfluramine treatment. Int J Obes Relat Metab Disord. 23:1999;S178.
18. Ryan D.H., Bray G.A., Helmcke F., Sander G., Volaufova J., Greenway F., Subramaniam P., Glancy D.L. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res. 7:1999;313-322.
19. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. J Am Coll Cardiol. 34:1999;2088-2095.
20. Gardin J.M., Weissman N.J., Leung C., Panza J.A., Fernicola D., Davis K.D., Constantine G., Reid C. One year echocardiographic follow-up of patients treated with anorexigens. Int J Obes Relat Metab Disord. 24:2000;S188.
21. Mast S.T., Jollis J.G., Ryan T., Anstrom K.J., Crary J.L. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med. 134:2001;261-266.
22. McDonald P.C., Wilson J.E., McManus B.M. Fen-phen valve disease: a real entity? Pathol Case Rev. 6:2001;281-286.
23. Jollis J.G., Landolfo C.K., Kisslo J., Constantine G.D., Davis K.D., Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation. 101:2000;2071-2077.
24. Asinger R.W. The fen-phen controversy: is regression another piece of the puzzle? Mayo Clin Proc. 74:1999;1302-1304.
25. Garon C.F., Oury J.H., Duran C.M. Virus-like particles in the mitral and tricuspid valves explanted from a patient treated with fenfluramine-phentermine. J Heart Valve Dis. 8:1999;232.
26. Steffee C.H., Singh H.K., Chitwood W.R. Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol. 8:1999;245-253.
27. Fowles R.E., Cloward T.V., Yowell R.L. Endocardial fibrosis associated with fenfluramine-phentermine. N Engl J Med. 338:1998;1316.
28. Volmar K.E., Hutchins G.M. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med. 125:2001;1555-1561.
29. McDonald P.C., Wilson J.E., Gao M., Spinelli J.J., Wiebe H., McNeill S., McManus B.M. The challenge of defining normality of human mitral and aortic valves: geometrical and compositional analysis. Cardiovasc Pathol. 11(4):2002;193-209.
30. Lin H., Ignatescu M., Wilson J.E., Roberts C.R., Horley K.J., Winters G.L., Costanzo M.R., McManus B.M. Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: geographic relationship to vessel wall proteoglycans. J Heart Lung Transplant. 15:1996;1223-1232.
31. Lin H., Wilson J.E., Roberts C.R., Horley K.J., Winters G.L., Costanzo M.R., McManus B.M. Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allograft: distinctness as compared to native atherosclerosis. J Heart Lung Transplant. 15:1996;1233-1247.
32. Hanson T.P., Edwards B.S., Edwards J.E. Pathology of surgically excised mitral valves. One hundred consecutive cases. Arch Pathol Lab Med. 109:1985;823-828.
33. Olson L.J., Subramanian R., Ackermann D.M., Orszulak T.A., Edwards W.D. Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years. Mayo Clin Proc. 62:1987;22-34.
34. Anderson A.S., Krauss D., Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J. 134:1997;693-702.
35. Roberts W.C. A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol. 80:1997;251-256.
36. McMillan J.B., Lev M. The aging heart: II. The valves. J Gerontol. 19:1964;1-14.
37. Schenk K.E., Heinze G. Age-dependent changes of heart valves and heart size. Recent Adv Stud Cardiac Struct Metab. 10:1975;617-624.
38. Sahasakul Y., Edwards W.D., Naessens J.M., Tajik A.J. Age-related changes in aortic and mitral valve thickness: implications for two-dimensional echocardiography based on an autopsy study of 200 normal human hearts. Am J Cardiol. 62:1988;424-430.
39. Roberts W.C. Valvular, subvalvular and supravalvular aortic stenosis: morphologic features. Cardiovasc Clin. 5:1973;97-126.
40. Rose A.G. Etiology of valvular heart disease. Curr Opin Cardiol. 11:1996;98-113.
41. Virmani R., Atkinson J.B., Forman M.B. The pathology of mitral valve prolapse. Herz. 13:1988;215-226.
42. Kulke M.H., Mayer R.J. Medical progress: carcinoid tumors. N Engl J Med. 340:1999;858-868.
43. Lundin L., Funa K., Hansson H.E., Wilander E., Oberg K. Histochemical and immunohistochemical morphology of carcinoid heart disease. Pathol Res Pract. 187:1991;73-77.